使用“即插即用”模块化聚二甲基硅氧烷泵直接检测血液中的癌症生物标志物。
Direct detection of cancer biomarkers in blood using a "place n play" modular polydimethylsiloxane pump.
机构信息
State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Changning Road 865, Shanghai 200050, China.
出版信息
Biomicrofluidics. 2013 May 23;7(3):34105. doi: 10.1063/1.4807803. eCollection 2013.
Cancer biomarkers have significant potential as reliable tools for the early detection of the disease and for monitoring its recurrence. However, most current methods for biomarker detection have technical difficulties (such as sample preparation and specific detector requirements) which limit their application in point of care diagnostics. We developed an extremely simple, power-free microfluidic system for direct detection of cancer biomarkers in microliter volumes of whole blood. CEA and CYFRA21-1 were chosen as model cancer biomarkers. The system automatically extracted blood plasma from less than 3 μl of whole blood and performed a multiplex sample-to-answer assay (nano-ELISA (enzyme-linked immunosorbent assay) technique) without the use of external power or extra components. By taking advantage of the nano-ELISA technique, this microfluidic system detected CEA at a concentration of 50 pg/ml and CYFRA21-1 at a concentration of 60 pg/ml within 60 min. The combination of PnP polydimethylsiloxane (PDMS) pump and nano-ELISA technique in a single microchip system shows great promise for the detection of cancer biomarkers in a drop of blood.
癌症生物标志物作为可靠的疾病早期检测和监测疾病复发的工具具有重要潜力。然而，目前大多数生物标志物检测方法都存在技术难题（例如样本制备和特定检测器的要求），这限制了它们在即时诊断中的应用。我们开发了一种极其简单、无需电源的微流控系统，可直接检测微升全血中的癌症生物标志物。我们选择 CEA 和 CYFRA21-1 作为模型癌症生物标志物。该系统可自动从少于 3μl 的全血中提取血浆，并进行多重样本到答案分析（纳米酶联免疫吸附测定 (ELISA) 技术），无需外部电源或额外组件。通过利用纳米 ELISA 技术，该微流控系统可在 60 分钟内检测到浓度为 50pg/ml 的 CEA 和浓度为 60pg/ml 的 CYFRA21-1。在单个微芯片系统中结合 PnP 聚二甲基硅氧烷 (PDMS) 泵和纳米 ELISA 技术，为一滴血中癌症生物标志物的检测带来了巨大的希望。
Zotero 插件